Epic Test Code LAB160 Mumps Virus Antibody, IgG, Serum
Additional Codes
MML Code: MPPG
LIS Code: MVSA
NY State Approved
YesPerforming Laboratory
Mayo Clinic Laboratories in RochesterReporting Name
Mumps Ab, IgG, SMethod Name
Multiplex Flow Immunoassay (MFI)
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 14 days |
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Type
SerumSpecimen Minimum Volume
0.4 mL
Reference Values
Vaccinated: Positive (≥1.1 AI)
Unvaccinated: Negative (≤0.8 AI)
Reference values apply to all ages.
Report Available
Same day/1 to 3 daysDay(s) Performed
Monday through Saturday
CPT Code Information
86735
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Heat-inactivated specimen | Reject |
Useful For
Determination of postimmunization immune response of individuals to the mumps vaccine
Documentation of previous infection with mumps virus in an individual with no previous record of immunization to mumps virus
Clinical Information
The mumps virus is a member of the Paramyxoviridae family of viruses, which include parainfluenza virus serotypes 1-4, measles, respiratory syncytial virus, and metapneumovirus. Mumps is highly infectious among unvaccinated individuals and is typically transmitted through inhalation of infected respiratory droplets or secretions. Following an approximately 2-week incubation period, symptom onset is typically acute with a prodrome of low-grade fever, headache, and malaise.(1,2) Painful enlargement of the salivary glands, the hallmark of mumps, occurs in approximately 60% to 70% of infections and in 95% of patients with symptoms. Testicular pain (orchitis) occurs in approximately 15% to 30% of postpubertal men and abdominal pain (oophoritis) is found in 5% of postpubertal women.(1) Other complications include mumps-associated pancreatitis (<5% of cases) and central nervous system disease (meningitis <10% and encephalitis <1%).
Widespread routine immunization of infants with attenuated mumps virus has dramatically decreased the number of reported mumps cases in the United States. However, outbreaks continue to occur, indicating persistence of the virus in the general population.
Laboratory diagnosis of mumps is typically accomplished by detection of IgM- and IgG-class antibodies to the mumps virus. However, due to the widespread mumps vaccination program, in clinically suspected cases of acute mumps infection, serologic testing should be supplemented with virus isolation in culture or detection of viral nucleic acid by polymerase chain reaction testing in throat, saliva, or urine specimens.
Interpretation
Positive:
The presence of detectable IgG-class antibodies indicates prior exposure to the mumps virus through infection or immunization. Individuals testing positive are considered immune to the mumps virus.
Equivocal:
Submit an additional specimen for testing in 10 to 14 days to demonstrate IgG seroconversion if recently vaccinated or if otherwise clinically indicated.
Negative:
The absence of detectable IgG-class antibodies suggests no prior exposure to the mumps virus or the lack of a specific immune response to immunization.
Cautions
Mumps virus shares antigenic relationships with other viruses of the paramyxovirus group; therefore, serologic cross-reactions are possible, but uncommon with this test procedure.(2)
Immunoglobulin G-class antibodies to mumps virus may be present in serum specimens from individuals who have received blood products within the past several months but have not been immunized or experienced past infection with this virus.
Serum samples drawn early during acute phase of infection may be negative for IgG-class antibodies to this virus.
Supportive Data
To evaluate the accuracy of the BioPlex mumps IgG multiplex flow immunoassay (MFI), 500 prospective serum samples were analyzed in a blinded fashion by the SeraQuest mumps IgG enzyme immunoassay (EIA) and the BioPlex mumps IgG assay. Samples with discordant results after initial testing were repeated by both assays during the same freeze/thaw cycle. Further discrepancies were evaluated by the mumps IgG VIDAS enzyme-linked fluorescent immunoassay (ELFA; bioMerieux, Inc). The results are summarized below:
Table.
 BioPlex Mumps IgG |
SeraQuest Mumps IgG EIA |
||
Positive |
Negative |
Equivocal |
|
Positive |
412 |
4(a) |
8 |
Negative |
3(b) |
48 |
3 |
Equivocal |
5 |
6 |
11 |
(a) All 4 samples tested positive by VIDAS Mumps IgG ELFA
(b) One of 3 samples tested negative by the VIDAS Mumps IgG ELFA
Sensitivity: 98.1% (412/420); 95% CI: 96.2% to 99.1%
Specificity: 82.8% (48/58); 95% CI: 70.9% to 90.6%
Overall Percent Agreement: 94.2% (471/500); 95% CI: 91.8% to 96.0%